Basic Information
| Drug ID | DDPD00601 |
|
| Drug Name | Linezolid | |
| Molecular Weight | 337.3461 | |
| Molecular Formula | C16H20FN3O4 | |
| CAS Number | 165800-03-3 | |
| SMILES | CC(=O)NC[C@H]1CN(C(=O)O1)C1=CC(F)=C(C=C1)N1CCOCC1 | |
| External Links | ||
| DRUGBANK | DB00601 | |
| T3DB | T3D2675 | |
| PubChem Compound | 441401 | |
| PDR | 2341 | |
| Drugs.com | Drugs.com Drug Page | |
Experimental Physicochemical Property
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Reference |
|---|---|---|---|---|---|
| Log P | 0.9 | - | 0.9 | - | DRUGBANK |
| Water Solubility | 3000.0 | mg/L | 3 | mg/ml | DRUGBANK |
Pharmacokinetic/ Toxicokinetic Property
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Annotation | Factor | Reference |
|---|---|---|---|---|---|---|---|
| Bioavailability | 100.0 | % | ~100 | % | PO, oral; | DRUGBANK | Bioavailability | 100.0 | % | 100.0 | % | PO, oral; | The Pharmacological Basis of Therapeutics |
| C Max | 16000.0 | ng/ml | 16±4 | mcg/ml | PO, oral; | The Pharmacological Basis of Therapeutics | C Max | 15000.0 | ng/ml | 15±3 | mcg/ml | intravenous injection, IV; gram-positive infection; | The Pharmacological Basis of Therapeutics |
| T Max | 1.5 | h | 1-2 | h | PO, oral; | DRUGBANK | T Max | 1.4 | h | 1.4±0.5 | h | PO, oral; | The Pharmacological Basis of Therapeutics |
| Clearance | 0.13 | L/h/kg | 2.1±0.8 | ml/min/kg | Children ↑ ; | The Pharmacological Basis of Therapeutics | Clearance | 0.11 | L/h/kg | 1.8 | ml/min/kg | intravenous injection, IV; human, homo sapiens; | Human Intravenous Pharmacokinetic Dataset |
| Volume of Distribution | 45.0 | L | 40-50 | L | normal,healthy; adults; | DRUGBANK | Volume of Distribution | 0.64 | L/kg | 0.57-0.71 | L/kg | The Pharmacological Basis of Therapeutics | Volume of Distribution | 0.58 | L/kg | 0.58 | L/kg | intravenous injection, IV; human, homo sapiens; | Human Intravenous Pharmacokinetic Dataset |
| Half-life | 5.0 | h | 4.5-5.5 | h | DRUGBANK | Half-life | 5.2 | h | 5.2±1.7 | h | Children ↓ ; | The Pharmacological Basis of Therapeutics | Half-life | 4.5 | h | 4.5 | h | intravenous injection, IV; human, homo sapiens; | Human Intravenous Pharmacokinetic Dataset |
| Eliminate Route | 35.0 | % | 35 | % | Urinary excretion; Unchanged drug; | The Pharmacological Basis of Therapeutics | |
| Protein Binding | 31.0 | % | 31 | % | DRUGBANK | Protein Binding | 31.0 | % | 31 | % | The Pharmacological Basis of Therapeutics |
Maximum Dosage
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Annotation | Frequency | Brand Name | Component | Reference |
|---|---|---|---|---|---|---|---|---|---|
| Max dose for neonates | 10.0 | mg/kg | 10 | mg/kg | PO, oral;intravenous injection, IV; | q8h | Zyvox | linezolid | PDR |
| Max dose for infants | 10.0 | mg/kg | 10 | mg/kg | PO, oral;intravenous injection, IV; | q8h | Zyvox | linezolid | PDR |
| Max dose for children | 1200.0 | mg/day | 1200 | mg/day | PO, oral;intravenous injection, IV; | Zyvox | linezolid | PDR | |
| Max dose for children | 10.0 | mg/kg | 10 | mg/kg | PO, oral;intravenous injection, IV; | q8h | Zyvox | linezolid | PDR |
| Max dose for children | 600.0 | mg | 600 | mg | PO, oral;intravenous injection, IV; | q8h | Zyvox | linezolid | PDR |
| Max dose for adolescents | 1200.0 | mg/day | 1200 | mg/day | PO, oral;intravenous injection, IV; | Zyvox | linezolid | PDR | |
| Max dose for adults | 1200.0 | mg/day | 1200 | mg/day | PO, oral;intravenous injection, IV; | Zyvox | linezolid | PDR | |
| Max dose for geriatric | 1200.0 | mg/day | 1200 | mg/day | PO, oral;intravenous injection, IV; | Zyvox | linezolid | PDR |
Drug Property Radar Chart
Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1